Ultragenyx Pharmaceutical (RARE) Operating Expenses (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Operating Expenses data on file, last reported at $305.0 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 8.16% year-over-year to $305.0 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 11.5% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 10.22% from the prior year.
• Operating Expenses for Q1 2026 stood at $305.0 million, down from $320.6 million in the prior quarter.
• Over the last five years, Operating Expenses for RARE reached as high as $330.8 million in Q3 2025 and fell as low as $216.6 million in Q1 2022.
• Historically, Operating Expenses has averaged $272.0 million across 5 years, with a median of $271.5 million in 2024.
• Across the five-year window, Operating Expenses soared 84.15% in 2022 and declined 23.0% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $249.0 million in 2022, then climbed by 0.0% to $249.0 million in 2023, then advanced by 15.25% to $287.0 million in 2024, then rose by 11.71% to $320.6 million in 2025, then retreated by 4.85% to $305.0 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $305.0 million in Q1 2026, $320.6 million in Q4 2025, and $330.8 million in Q3 2025.